Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

Continuous, subcutaneous (SC) levodopa/carbidopa infusion with ND0612 is under development as a treatment for patients with Parkinson's disease (PD) and motor fluctuations.

[1]  W. Poewe,et al.  Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study , 2020, Journal of Parkinson's disease.

[2]  A. Deeb,et al.  Impact of Insulin Injection and Infusion Routines on Lipohypertrophy and Glycemic Control in Children and Adults with Diabetes , 2019, Diabetes Therapy.

[3]  A. Antonini,et al.  Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach , 2018, Current medical research and opinion.

[4]  R. Bhidayasiri,et al.  Practical management of adverse events related to apomorphine therapy. , 2016, Parkinsonism & related disorders.

[5]  K. Chaudhuri,et al.  Effective Delivery of Apomorphine in the Management of Parkinson Disease: Practical Considerations for Clinicians and Parkinson Nurses , 2015, Clinical neuropharmacology.

[6]  J. Epstein,et al.  Semaphorin signaling in cardiovascular development. , 2015, Cell metabolism.

[7]  W. Poewe,et al.  Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release , 2014, Parkinson's disease.

[8]  Daniel Weintraub,et al.  Questionnaire for impulsive‐compulsive disorders in Parkinson's Disease–Rating Scale , 2012, Movement disorders : official journal of the Movement Disorder Society.

[9]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[10]  M. Cohen,et al.  Cutaneous Side-effects of Immunomodulators in MS. , 2011, International MS journal.

[11]  R. Hauser,et al.  Determination of minimal clinically important change in early and advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[12]  D. Pineda-Alvarez,et al.  Analysis of genotype–phenotype correlations in human holoprosencephaly , 2010, American journal of medical genetics. Part C, Seminars in medical genetics.

[13]  I Guilhem,et al.  Technical risks with subcutaneous insulin infusion. , 2006, Diabetes & metabolism.

[14]  R. Hauser,et al.  Parkinson's disease home diary: Further validation and implications for clinical trials , 2004, Movement disorders : official journal of the Movement Disorder Society.

[15]  M. Behari,et al.  Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS). , 2003, Sleep medicine.

[16]  L. Seeberger,et al.  A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.

[17]  T. Cooper.  Department of Health, Education, and Welfare. , 1976, Military medicine.